Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised,phase 3 study |
| |
| Affiliation: | 1. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;2. CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d''Hématologie, Toulouse, France;3. Clínica Universidad de Navarra, Navarra, CCUN, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain;4. Department of Hematology, Ankara University, Ankara, Turkey;5. General Faculty Hospital, and First Faculty of Medicine, Charles University, Prague, Czech Republic;6. Service d''Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France;7. Oslo Myeloma Center, Department of Haematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway;8. Hematology Department, CHU Nantes, Nantes, France;9. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;10. Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan;11. Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic;12. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy;13. Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia;14. Sanofi R&D, Vitry, France |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
